ST Spyre Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Spyre Therapeutics, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €9.1bn. The latest transaction was reported on 10 August 2026 (Levée d'options). Among the most active insiders: Turtle Cameron. Every trade is free.
Analyst consensus: bullish or bearish? Analysts rate Spyre Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$124.71.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 August 2026
All Executives67 Thresholds0 Prospectus0 Other0
Declarations 67 total
◇ Director · Executives · 7 Aug 2026
5,000 shares @ US$10.39 0.0006% mcap 1.9% of flow Common Stock SEC:0001636282-26-000102:0
▼ Director · Executives · 7 Aug 2026
5,000 shares @ US$104.47 0.0057% mcap 19.2% of flow Common Stock SEC:0001636282-26-000102:1
▼ Director · Executives · 7 Aug 2026
10,000 shares @ US$104.68 0.012% mcap 38.4% of flow Common Stock SEC:0001636282-26-000102:3
▼ Director · Executives · 7 Aug 2026
8,000 shares @ US$104.38 0.0092% mcap 30.6% of flow Common Stock SEC:0001636282-26-000102:2
▼ Chief Executive Officer · Executives · 3 Aug 2026
1,392 shares @ US$96.82 0.0016% mcap 2.8% of flow Common Stock SEC:0001636282-26-000099:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
800 shares @ US$93.97 0.0009% mcap 1.6% of flow Common Stock SEC:0001636282-26-000099:0
◇ Chief Financial Officer · Executives · 3 Aug 2026
7,500 shares @ US$14.50 0.0013% mcap 3.3% of flow Common Stock SEC:0001636282-26-000100:0
▼ Chief Financial Officer · Executives · 3 Aug 2026
5,100 shares @ US$95.21 0.0059% mcap 14.6% of flow Common Stock SEC:0001636282-26-000100:1
▼ Chief Financial Officer · Executives · 3 Aug 2026
2,300 shares @ US$96.30 0.0027% mcap 6.7% of flow Common Stock SEC:0001636282-26-000100:2
▼ Chief Financial Officer · Executives · 3 Aug 2026
100 shares @ US$97.10 0.0001% mcap 0.3% of flow Common Stock SEC:0001636282-26-000100:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
7,157 shares @ US$95.10 0.0083% mcap 14.1% of flow Common Stock SEC:0001636282-26-000099:1
▼ Chief Executive Officer · Executives · 3 Aug 2026
5,635 shares @ US$95.93 0.0066% mcap 11.2% of flow Common Stock SEC:0001636282-26-000099:2
▼ Chief Executive Officer · Executives · 3 Aug 2026
16 shares @ US$97.46 0.0000% mcap 0.0% of flow Common Stock SEC:0001636282-26-000099:4
▼ Chief Financial Officer · Executives · 25 Jun 2026
10,000 shares Common Stock SEC:0001853327-26-000008:2
◇ Chief Financial Officer · Executives · 25 Jun 2026
15,000 shares Common Stock SEC:0001853327-26-000008:0
▼ Chief Financial Officer · Executives · 25 Jun 2026
5,000 shares Common Stock SEC:0001853327-26-000008:1
● Officer · Executives · 25 Jun 2026
15,000 shares @ US$87.132 0.015% mcap 100.0% of flow Common SEC144:0001950047-26-006485
● Director · Executives · 23 Jun 2026
4,684,781 shares @ US$85.31 4.72% mcap 100.0% of flow Common SEC144:0001104659-26-076969
● Director · Executives · 23 Jun 2026
666,680 shares Common Stock SEC:0001104659-26-076967:0
▼ Director · Executives · 23 Jun 2026
4,684,781 shares Common Stock SEC:0001104659-26-076967:1
▼ Director · Executives · 22 Jun 2026
20,000 shares Common Stock SEC:0001636282-26-000084:0
● Director · Executives · 22 Jun 2026
20,000 shares @ US$88.34 0.021% mcap 100.0% of flow Common SEC144:0001950047-26-006375
◇ Chief Financial Officer · Executives · 1 Jun 2026
7,500 shares @ US$14.50 16.9% of flow Common Stock SEC:0001636282-26-000076:0
▼ Chief Financial Officer · Executives · 1 Jun 2026
1,801 shares @ US$69.75 19.6% of flow Common Stock SEC:0001636282-26-000076:1
▼ Chief Financial Officer · Executives · 1 Jun 2026
2,599 shares @ US$70.77 28.7% of flow Common Stock SEC:0001636282-26-000076:2
25 of 67 declarations
Load more (42 remaining) About Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. is a company focused on developing innovative therapies for serious diseases. It is listed on the XNAS market.